
Sensible Biotechnologies
Sensible Biotechnologies is a YC Summer 2021 (S21) company. Based in Oxford, England, United Kingdom. Team of 24.
About Sensible Biotechnologies
Summary
Sensible Biotechnologies builds a cell-based platform for designing and manufacturing mRNA therapeutics. Where conventional synthetic mRNA production hits walls on stability, purity, and immune response, Sensible uses living cells as production factories to generate mRNA that is more stable and less immunogenic at scale. The platform targets drug developers who need manufacturable mRNA candidates that current cell-free synthesis cannot deliver.
Go-to-market
Sensible Biotechnologies sells to pharmaceutical and bioprocess partners, with Sartorius Stedim Biotech engaged for scale-up of its manufacturing platform.
From the Y Combinator listing
Unlocking the next generation of mRNA medicines
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Facts
- Healthcare / Healthcare -> Therapeutics
- Oxford, England, United Kingdom
- 24
- Active
- Early
Founders (2)
- Marian Kupculak
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works